Researchers describe as many as four subgroups of HER2+ breast cancer with varying responses and benefits resulting from combined anti-HER2 targeted therapy and chemotherapy.
Researchers describe as many as four subgroups of HER2+ breast cancer with varying responses and benefits resulting from combined anti-HER2 targeted therapy and chemotherapy.